Cargando…

Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

INTRODUCTION: Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting molecules are under development to detect and treat metastatic castration resistant prostate cancer (mCRPC). We investigated the tissue kinetics of a small m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zechmann, Christian M., Afshar-Oromieh, Ali, Armor, Tom, Stubbs, James B., Mier, Walter, Hadaschik, Boris, Joyal, John, Kopka, Klaus, Debus, Jürgen, Babich, John W., Haberkorn, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052014/
https://www.ncbi.nlm.nih.gov/pubmed/24577951
http://dx.doi.org/10.1007/s00259-014-2713-y
_version_ 1782320168979922944
author Zechmann, Christian M.
Afshar-Oromieh, Ali
Armor, Tom
Stubbs, James B.
Mier, Walter
Hadaschik, Boris
Joyal, John
Kopka, Klaus
Debus, Jürgen
Babich, John W.
Haberkorn, Uwe
author_facet Zechmann, Christian M.
Afshar-Oromieh, Ali
Armor, Tom
Stubbs, James B.
Mier, Walter
Hadaschik, Boris
Joyal, John
Kopka, Klaus
Debus, Jürgen
Babich, John W.
Haberkorn, Uwe
author_sort Zechmann, Christian M.
collection PubMed
description INTRODUCTION: Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting molecules are under development to detect and treat metastatic castration resistant prostate cancer (mCRPC). We investigated the tissue kinetics of a small molecule inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[(124)I]iodophenyl)ureido)pentyl)ureido)pentanedioicacid; MIP-1095) using PET/CT to estimate radiation dosimetry for the potential therapeutic use of (131)I-MIP-1095 in men with mCRPC. We also report preliminary safety and efficacy of the first 28 consecutive patients treated under a compassionate-use protocol with a single cycle of (131)I-MIP-1095. METHODS: Sixteen patients with known prostate cancer underwent PET/CT imaging after i.v. administration of (124)I-MIP-1095 (mean activity: 67.4 MBq). Each patient was scanned using PET/CT up to five times at 1, 4, 24, 48 and 72 h post injection. Volumes of interest were defined for tumor lesions and normal organs at each time point followed by dose calculations using the OLINDA/EXM software. Twenty-eight men with mCRPC were treated with a single cycle of (131)I-MIP-1095 (mean activity: 4.8 GBq, range 2 to 7.2 GBq) and followed for safety and efficacy. Baseline and follow up examinations included a complete blood count, liver and kidney function tests, and measurement of serum PSA. RESULTS: I-124-MIP-1095 PET/CT images showed excellent tumor uptake and moderate uptake in liver, proximal intestine and within a few hours post-injection also in the kidneys. High uptake values were observed only in salivary and lacrimal glands. Dosimetry estimates for I-131-MIP-1095 revealed that the highest absorbed doses were delivered to the salivary glands (3.8 mSv/MBq, liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq). The absorbed dose calculated for the red marrow was 0.37 mSv/MBq. PSA values decreased by >50 % in 60.7 % of the men treated. Of men with bone pain, 84.6 % showed complete or moderate reduction in pain. Hematological toxicities were mild. Of men treated, 25 % had a transient slight to moderate dry mouth. No adverse effects on renal function were observed. CONCLUSION: Based on the biodistribution and dose calculations of the PSMA-targeted small molecule (124)I-MIP-1095 therapy with the authentic analog (131)I-MIP-1095 enables a targeted tumor therapy with unprecedented doses delivered to the tumor lesions. Involved lymph node and bone metastases were exposed to estimated absorbed doses upwards of 300 Gy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-014-2713-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4052014
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-40520142014-06-18 Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy Zechmann, Christian M. Afshar-Oromieh, Ali Armor, Tom Stubbs, James B. Mier, Walter Hadaschik, Boris Joyal, John Kopka, Klaus Debus, Jürgen Babich, John W. Haberkorn, Uwe Eur J Nucl Med Mol Imaging Original Article INTRODUCTION: Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting molecules are under development to detect and treat metastatic castration resistant prostate cancer (mCRPC). We investigated the tissue kinetics of a small molecule inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[(124)I]iodophenyl)ureido)pentyl)ureido)pentanedioicacid; MIP-1095) using PET/CT to estimate radiation dosimetry for the potential therapeutic use of (131)I-MIP-1095 in men with mCRPC. We also report preliminary safety and efficacy of the first 28 consecutive patients treated under a compassionate-use protocol with a single cycle of (131)I-MIP-1095. METHODS: Sixteen patients with known prostate cancer underwent PET/CT imaging after i.v. administration of (124)I-MIP-1095 (mean activity: 67.4 MBq). Each patient was scanned using PET/CT up to five times at 1, 4, 24, 48 and 72 h post injection. Volumes of interest were defined for tumor lesions and normal organs at each time point followed by dose calculations using the OLINDA/EXM software. Twenty-eight men with mCRPC were treated with a single cycle of (131)I-MIP-1095 (mean activity: 4.8 GBq, range 2 to 7.2 GBq) and followed for safety and efficacy. Baseline and follow up examinations included a complete blood count, liver and kidney function tests, and measurement of serum PSA. RESULTS: I-124-MIP-1095 PET/CT images showed excellent tumor uptake and moderate uptake in liver, proximal intestine and within a few hours post-injection also in the kidneys. High uptake values were observed only in salivary and lacrimal glands. Dosimetry estimates for I-131-MIP-1095 revealed that the highest absorbed doses were delivered to the salivary glands (3.8 mSv/MBq, liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq). The absorbed dose calculated for the red marrow was 0.37 mSv/MBq. PSA values decreased by >50 % in 60.7 % of the men treated. Of men with bone pain, 84.6 % showed complete or moderate reduction in pain. Hematological toxicities were mild. Of men treated, 25 % had a transient slight to moderate dry mouth. No adverse effects on renal function were observed. CONCLUSION: Based on the biodistribution and dose calculations of the PSMA-targeted small molecule (124)I-MIP-1095 therapy with the authentic analog (131)I-MIP-1095 enables a targeted tumor therapy with unprecedented doses delivered to the tumor lesions. Involved lymph node and bone metastases were exposed to estimated absorbed doses upwards of 300 Gy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-014-2713-y) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2014-02-28 2014 /pmc/articles/PMC4052014/ /pubmed/24577951 http://dx.doi.org/10.1007/s00259-014-2713-y Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Zechmann, Christian M.
Afshar-Oromieh, Ali
Armor, Tom
Stubbs, James B.
Mier, Walter
Hadaschik, Boris
Joyal, John
Kopka, Klaus
Debus, Jürgen
Babich, John W.
Haberkorn, Uwe
Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
title Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
title_full Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
title_fullStr Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
title_full_unstemmed Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
title_short Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
title_sort radiation dosimetry and first therapy results with a (124)i/(131)i-labeled small molecule (mip-1095) targeting psma for prostate cancer therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052014/
https://www.ncbi.nlm.nih.gov/pubmed/24577951
http://dx.doi.org/10.1007/s00259-014-2713-y
work_keys_str_mv AT zechmannchristianm radiationdosimetryandfirsttherapyresultswitha124i131ilabeledsmallmoleculemip1095targetingpsmaforprostatecancertherapy
AT afsharoromiehali radiationdosimetryandfirsttherapyresultswitha124i131ilabeledsmallmoleculemip1095targetingpsmaforprostatecancertherapy
AT armortom radiationdosimetryandfirsttherapyresultswitha124i131ilabeledsmallmoleculemip1095targetingpsmaforprostatecancertherapy
AT stubbsjamesb radiationdosimetryandfirsttherapyresultswitha124i131ilabeledsmallmoleculemip1095targetingpsmaforprostatecancertherapy
AT mierwalter radiationdosimetryandfirsttherapyresultswitha124i131ilabeledsmallmoleculemip1095targetingpsmaforprostatecancertherapy
AT hadaschikboris radiationdosimetryandfirsttherapyresultswitha124i131ilabeledsmallmoleculemip1095targetingpsmaforprostatecancertherapy
AT joyaljohn radiationdosimetryandfirsttherapyresultswitha124i131ilabeledsmallmoleculemip1095targetingpsmaforprostatecancertherapy
AT kopkaklaus radiationdosimetryandfirsttherapyresultswitha124i131ilabeledsmallmoleculemip1095targetingpsmaforprostatecancertherapy
AT debusjurgen radiationdosimetryandfirsttherapyresultswitha124i131ilabeledsmallmoleculemip1095targetingpsmaforprostatecancertherapy
AT babichjohnw radiationdosimetryandfirsttherapyresultswitha124i131ilabeledsmallmoleculemip1095targetingpsmaforprostatecancertherapy
AT haberkornuwe radiationdosimetryandfirsttherapyresultswitha124i131ilabeledsmallmoleculemip1095targetingpsmaforprostatecancertherapy